Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL221282 | 0.94 | MAPT (0.57) | MAPTSMN1; SMN2L3MBTL1CYP3A4LMNA | |
| Butane SCHEMBL11694245 | 0.89 | MAPT (0.53) | MAPTSMN1; SMN2L3MBTL1CYP3A4LMNA | |
| SCHEMBL10389933 | 0.89 | SMN1; SMN2 (0.83) | MAPTSMN1; SMN2L3MBTL1LMNACYP1A2 | |
| SCHEMBL8413590 | 0.82 | MAPT (0.56) | MAPTSMN1; SMN2L3MBTL1LMNAHPGD | |
| SCHEMBL8051337 | 0.82 | SMN1; SMN2 (0.70) | MAPTSMN1; SMN2L3MBTL1HPGDALDH1A1 | |
| SCHEMBL13267783 | 0.81 | MAPT (1.00) | MAPTSMN1; SMN2L3MBTL1LMNACYP1A2 | |
| SCHEMBL2633141 | 0.81 | SMN1; SMN2 (0.70) | MAPTSMN1; SMN2L3MBTL1LMNAHPGD | |
| SCHEMBL15085369 | 0.81 | SMN1; SMN2 (0.77) | MAPTSMN1; SMN2L3MBTL1HPGDALDH1A1 | |
| SCHEMBL1928026 | 0.81 | MAPT (1.00) | MAPTSMN1; SMN2L3MBTL1LMNACYP1A2 | |
| SCHEMBL28427073 | 0.81 | MAPT (0.70) | MAPTSMN1; SMN2L3MBTL1LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8227606-B2 | Arginine derivatives with NP-1 antagonistic activity | ARK THERAPEUTICS, LTD. (GB) | 2012-07-24 | — | — | US | disclosed |
| US-20120122862-A1 | ARGININE DERIVATIVES WITH NP-I ANTAGONISTIC ACTIVITY | GB06/019611.7 THERAPIES LIMITED (GB) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122862-A1 | ARGININE DERIVATIVES WITH NP-I ANTAGONISTIC ACTIVITY | NPFFR1, NPR1, ARG1 | MAPT 4118/4885SMN1; SMN2 3003/4885L3MBTL1 3182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.